Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q4 2023
Holdings as of Dec 31, 2023, filed Feb 14, 2024. Long positions only; changes compare share counts with Q3 2023.
- Positions
- 34
- −5 vs. Q3 2023
- Portfolio value
- $586.7M
- +$55.1M (+10.4%) vs. Q3 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ALPNAlpine Immune Sciences, Inc. | COM | 3,703,433 | $70.6M | 12.0% | +624,800+20.3% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 500,000 | $41.7M | 7.1% | −100,000−16.7% | Reduced | History |
| URGNUroGen Pharma Ltd. | COM | 2,620,545 | $39.3M | 6.7% | 00.0% | Unchanged | History |
| PLRXPliant Therapeutics, Inc. | COM | 1,823,184 | $33.0M | 5.6% | +68,000+3.9% | Added | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 648,000 | $31.0M | 5.3% | −79,426−10.9% | Reduced | History |
| XENEXenon Pharmaceuticals Inc. | COM | 600,000 | $27.6M | 4.7% | +99,999+20.0% | Added | History |
| RAPTRAPT Therapeutics, Inc. | COM | 1,099,753 | $27.3M | 4.7% | −358,317−24.6% | Reduced | History |
| ALKSAlkermes plc. | SHS | 875,044 | $24.3M | 4.1% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 1,037,690 | $23.5M | 4.0% | −53,543−4.9% | Reduced | History |
| PCVXVaxcyte, Inc. | COM | 360,000 | $22.6M | 3.9% | −171,211−32.2% | Reduced | History |
| EOLSEvolus, Inc. | COM | 2,000,000 | $21.1M | 3.6% | −186,934−8.5% | Reduced | History |
| ANABAnaptysbio, Inc | COM | 976,981 | $20.9M | 3.6% | +82,648+9.2% | Added | History |
| IMCRImmunocore Holdings plc | ADS | 293,000 | $20.0M | 3.4% | +2,083+0.7% | Added | History |
| NGNENeurogene Inc. | COM | 994,229 | $19.3M | 3.3% | +994,229 | New | History |
| FOLDAmicus Therapeutics, Inc. | COM | 1,280,500 | $18.2M | 3.1% | +423,500+49.4% | Added | History |
| TRMLTourmaline Bio, Inc. | COM | 672,885 | $17.6M | 3.0% | +672,885 | New | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,550,000 | $16.6M | 2.8% | +1,550,000 | New | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 3,295,000 | $15.4M | 2.6% | 00.0% | Unchanged | History |
| OPTNOptiNose, Inc. | COM | 8,839,939 | $11.4M | 1.9% | 00.0% | Unchanged | History |
| APGEApogee Therapeutics, Inc. | COM | 400,000 | $11.2M | 1.9% | 00.0% | Unchanged | History |
| ARVNArvinas, Inc. | COM | 234,082 | $9.63M | 1.6% | +234,082 | New | History |
| KRTXKaruna Therapeutics, Inc. | COM | 30,250 | $9.57M | 1.6% | −30,250−50.0% | Reduced | History |
| VTGNVistagen Therapeutics, Inc. | COM | 1,858,735 | $9.55M | 1.6% | +1,858,735 | New | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 1,309,975 | $8.50M | 1.4% | +664,076+102.8% | Added | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 110,607 | $7.92M | 1.4% | −114,393−50.8% | Reduced | History |
| SRPTSarepta Therapeutics, Inc. | COM | 80,000 | $7.71M | 1.3% | −85,200−51.6% | Reduced | History |
| INSMINSMED Inc | COM PAR $.01 | 225,912 | $7.00M | 1.2% | −168,960−42.8% | Reduced | History |
| PBYIPuma Biotechnology, Inc. | COM | 1,093,273 | $4.73M | 0.8% | +1,093,273 | New | History |
| OCULOcular Therapeutix, Inc | COM | 700,000 | $3.12M | 0.5% | +700,000 | New | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 125,000 | $2.69M | 0.5% | +125,000 | New | History |
| ACLXArcellx, Inc. | COMMON STOCK | 48,264 | $2.68M | 0.5% | −239,236−83.2% | Reduced | History |
| MRUSMerus N.V. | COM | 20,000 | $550.0K | 0.1% | +20,000 | New | History |
| AXSMAxsome Therapeutics, Inc. | COM | 4,963 | $395.0K | 0.1% | +4,963 | New | History |
| MURAMural Oncology plc | ORD SHS | 11,509 | $68.1K | <0.1% | +11,509 | New | History |
Sold out since Q3 2023 (16)
Positions held at the end of Q3 2023 that are gone from this filing.
| Security | Class | Shares in Q3 2023 | Value in Q3 2023 | % of portfolio in Q3 2023 | History |
|---|---|---|---|---|---|
| PNTPOINT Biopharma Global Inc. | COM | 2,909,960 | $19.4M | 3.7% | History |
| ACRSAclaris Therapeutics, Inc. | COM | 1,691,768 | $11.6M | 2.2% | History |
| PTCTPTC Therapeutics, Inc. | COM | 500,000 | $11.2M | 2.1% | History |
| REPLReplimune Group, Inc. | COM | 638,495 | $10.9M | 2.1% | History |
| AKROAkero Therapeutics, Inc. | COM | 198,500 | $10.0M | 1.9% | History |
| OKUROnKure Therapeutics, Inc. | COM | 1,167,061 | $8.89M | 1.7% | History |
| GOSSGossamer Bio, Inc. | COM | 6,230,272 | $5.19M | 1.0% | History |
| IGMSIGM Biosciences, Inc. | COM | 615,317 | $5.14M | 1.0% | History |
| HRTXHeron Therapeutics, Inc. | COM | 4,737,368 | $4.88M | 0.9% | History |
| CERECerevel Therapeutics Holdings, Inc. | COM | 215,000 | $4.69M | 0.9% | History |
| ABOSAcumen Pharmaceuticals, Inc. | COM | 1,074,101 | $4.46M | 0.8% | History |
| GBIOGeneration Bio Co. | COM | 1,022,537 | $3.88M | 0.7% | History |
| MRTXMirati Therapeutics, Inc. | COM | 86,302 | $3.76M | 0.7% | History |
| TRMLTourmaline Bio, Inc. | COM | 1,000,000 | $2.81M | 0.5% | History |
| Gracell Biotechnologies Inc38406L103 | SPONSORED ADS | 579,667 | $1.67M | 0.3% | – |
| SLDBSolid Biosciences Inc. | COM NEW | 450,403 | $1.14M | 0.2% | History |